Key clinical point: A prognostication model identified genes in the tumor microenvironment that are strongly associated with worse prognosis in stage III, estrogen receptor-positive, HER2-negative breast cancer.
Major finding: Kaplan-Meier curves showed a significant survival difference in the high- and low-risk groups (hazard ratio, 2.878; P = .05), confirming the validity of the risk score modeling.
Study details: Assessment of a risk score model in 98 patients.
Disclosures: Dr. Abdou reported having no disclosures.
Abdou Y et al. ASCO-SITC. Poster A3.